Canada markets close in 1 hour 28 minutes

Defence Therapeutics Inc. (DTCFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.50000.0000 (0.00%)
As of 09:37AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close2.5000
Open2.3482
BidN/A x N/A
AskN/A x N/A
Day's Range2.5000 - 2.5000
52 Week Range2.3482 - 6.4078
Volume3,000
Avg. Volume147
Market Cap90.134M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1380
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    RETRANSMISSION: Defence's Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer

    The Company is issuing a clarification news release at the request of IIROC.Vancouver, British Columbia--(Newsfile Corp. - May 18, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focused on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to prote

  • Newsfile

    Defence Novel AccuVAC-PTE7 Vaccine Shows Complete Protection from Cervical Cancer

    Vancouver, British Columbia--(Newsfile Corp. - May 17, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceuticals company primarily focussed on the development of novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the development of novel dual-acting AccumTM-linked protein vaccine, AccuVAC-PTE7, dedicated to protect from cervical cancer (prophylactic vaccine) or to treat (therapeutic vac

  • Newsfile

    Defence Therapeutics Announces Issuance Of a U.S. Patent Covering Its Pioneering Vaccine Platform Technology

    Vancouver, British Columbia--(Newsfile Corp. - April 7, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company primarily focused on the development of novel vaccines and drug delivery technologies, is pleased to announced that the United States Patent and Trademark Office (USPTO) has granted patent number US 11,291,717 ('717) covering its breakthrough vaccine platform technology for the treatment/prevention of